Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2014 Feb 3;9(2):e87736. doi: 10.1371/journal.pone.0087736

Disruption of Myelin Leads to Ectopic Expression of KV1.1 Channels with Abnormal Conductivity of Optic Nerve Axons in a Cuprizone-Induced Model of Demyelination

Bandita Bagchi 1, Ahmed Al-Sabi 1, Seshu Kaza 1, Dimitri Scholz 3, Valerie B O'Leary 1, J Oliver Dolly 1,*, Saak V Ovsepian 1,2,4,*
Editor: Fernando de Castro5
PMCID: PMC3912067  PMID: 24498366

Abstract

The molecular determinants of abnormal propagation of action potentials along axons and ectopic conductance in demyelinating diseases of the central nervous system, like multiple sclerosis (MS), are poorly defined. Widespread interruption of myelin occurs in several mouse models of demyelination, rendering them useful for research. Herein, considerable myelin loss is shown in the optic nerves of cuprizone-treated demyelinating mice. Immuno-fluorescence confocal analysis of the expression and distribution of voltage-activated K+ channels (KV1.1 and 1.2 α subunits) revealed their spread from typical juxta-paranodal (JXP) sites to nodes in demyelinated axons, albeit with a disproportionate increase in the level of KV1.1 subunit. Functionally, in contrast to monophasic compound action potentials (CAPs) recorded in controls, responses derived from optic nerves of cuprizone-treated mice displayed initial synchronous waveform followed by a dispersed component. Partial restoration of CAPs by broad spectrum (4-aminopyridine) or KV1.1-subunit selective (dendrotoxin K) blockers of K+ currents suggest enhanced KV1.1-mediated conductance in the demyelinated optic nerve. Biophysical profiling of K+ currents mediated by recombinant channels comprised of different KV1.1 and 1.2 stoichiometries revealed that the enrichment of KV1 channels KV1.1 subunit endows a decrease in the voltage threshold and accelerates the activation kinetics. Together with the morphometric data, these findings provide important clues to a molecular basis for temporal dispersion of CAPs and reduced excitability of demyelinated optic nerves, which could be of potential relevance to the patho-physiology of MS and related disorders.

Introduction

Multiple sclerosis (MS) is a polyfactorial, devastating disease of the central nervous system (CNS). Despite being recognized almost two centuries ago, it remains the number one cause of non-traumatic neurological conditions in young adults [1], [2], with no radical treatment available. Throughout its protracted course, alternating deficits of axonal functions associated with demyelination deteriorates into conduction failure and progressive axonal degeneration, culminating in partial or complete sensory and motor incapacitation.

Functional and developmental studies have indicated essential roles for myelin in the rapid conduction of action potentials along thick myelinated axons [3], [4]. Enveloping neurites in a highly compartmented manner, myelin provides an effective shield essential for saltatory propagation of action potentials. There is considerable but conflicting evidence suggesting a stabilizing influence of voltage-activated KV1 currents on the excitability and conductivity of central and peripheral axons [5], [6], [7]. Mediated through channels produced by tetramerization of KV1.1 with 1.2 (and to a lesser extent 1.6) α subunits, and normally concentrated at the juxta-paranodes (JXPs), KV1 channels spread to internodes and nodal segments upon demyelination, causing impedance mismatch and disruption of action potential conduction [8], [9], [10]. Accordingly, indiscriminate pharmacological inhibition of K+ currents has been shown to restore the electrogenic functions of demyelinated axons, a mechanism that is implicated in some of the ameliorative influence of 4-aminopyridine (4-AP) and its analogues in MS patients [11], [12]. However, emerging evidence from animal studies suggests that the beneficial effects of therapeutically-relevant concentrations of 4-AP on axonal physiology are due to its action as a synaptic transmission enhancer [12], [13]. Indeed, low mM concentrations of 4-AP and 3,4-di-aminopyridine greatly facilitate neurotransmission at both excitatory and inhibitory synapses in the central and peripheral nervous systems [14], [15]. Of note, several studies also assigned therapeutic effects of 4-AP to its inhibition of immune cell proliferation [12], [16]. Inevitably, such broad-spectrum effects hampers the utilisation of 4-AP for discriminatory restoration of the functionality of demyelinated axons without off target effects.

A prevalence of optic neuropathies with functional disruptions during early MS [17], [18] kindled our interest in analysing the importance of KV1 currents in regulating electrophysiological properties of the optic nerve (ON) in a cuprizone-induced model of demyelination [19]. Our data demonstrate that demyelination is associated with an increase in K+ conductance mediated by ectopically expressed KV1 channels enriched with the KV1.1 α subunit. Evidence is presented for disruptive effects of KV1.1 on ON electrophysiology, and its critical influence on the biophysical and pharmacological profiles of KV1 currents in a heterologous expression system, signifying the pertinence of Kv1.1 subunit to conductive aberrations in demyelinating axons.

Materials and Methods

Animals and Induction of Demyelination

C57BL/6J male mice (8 weeks old) were obtained from Harlan (UK) and housed (21±2 °C, humidity 36±2% at 12/12-h light/dark cycle) in the Bio-Resource Unit of Dublin City University with food and water provided ad libitum. All procedures were approved by the University Ethics Committee, and licensed by the Department of Children and Health (Rep. of Ireland) in accordance with European Communities Council Directive of 24 November 1986 (86/609/ECC). Special efforts were made to minimize animal suffering and reduce the number of animals used. All animals received a Modified LabDiet®, with 0.2% cuprizone (Sigma, MO) supplemented to chow of the experimental (cuprizone treated) mice for 8 weeks, a time sufficient for induction of demyelination [19].

Measurement of the Myelin Content in Brain Samples

Myelin was purified by sucrose density gradient centrifugation [20]. In brief, after decapitation of anaesthetized mice (sodium pentobarbital 200 mg/kg, i.p.), brains were dissected out, weighed, frozen in liquid N2 and stored at -80 °C till used. The tissue was homogenized in 0.25 M sucrose/phosphate buffer saline (PBS, pH 7.4) and centrifuged for 10 min at 500× g, 4°C; after re-centrifugation of the supernatant (10 min at 10000× g), the resultant pellet was re-suspended in 10 volumes of the buffered 0.25 M sucrose. Following addition of an equal volume of 0.88 M sucrose and centrifugation (3 h at 100000× g), myelin was collected at the interface between the two sucrose layers. Then, it was re-suspended in 10 volumes of ice-cold de-ionized water and re-centrifuged (15000× g for 30 min, 4°C); this step was repeated 4 times to remove the residual sucrose, with the final pellet being dried and weighed.

Histochemistry and Transmission Electron Microscopy

Control and experimental mice (16 weeks old) were anaesthetized as above, perfused intra-cardially with PBS (pH 7.4) followed by fixation with 4% para-formaldehyde (PFA; Sigma, Ireland) in PBS, as described [21]. The brains were post-fixed overnight in PFA (4°C), cryo-protected (30% sucrose in PBS, 4°C for 24 h) and sectioned in mid sagittal plain (30 µm) followed by staining with luxol fast blue (LFB) or cresyl violet (CV) (n = 3 in each group), using protocols specified elsewhere [22], [23]. Sections were mounted, air-dried, immersed in xylene, and coverslipped with DPX mounting medium (Sigma, Ireland) and imaged using light microscope (Axioscope, Zeiss, Germany) with a DP72 colour camera (Olympus). For densitometry, colour images were converted into black and white, followed by analysis using intensity macro on randomly-defined regions of interests (ROI) in specified areas (ImageJ, NIH, USA).

For electron microscopy, perfusion of the mice was carried out according to the protocol [24] but with 1.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2). After careful removal from the cranial cavity, ON was kept overnight in this fixative solution (4°C), post-fixed by 1% OsO4 for 2 h, and dehydrated. The quality of fixation and gross morphology of ON were assessed with toluidine staining of cross-sections (15 µm) while the rest of the tissue was immersed in graded alcohol and embedded in Epon resin. Ultra-thin sections (2 µm) were cut and contrasted with uranyl acetate/lead citrate, before being imaged with an FEI Tecnai-12 electron microscope (Tecnai FEI, Nanoport, Oregon, USA). The ‘g’ ratio or myelination index was estimated as the ratio of inner axonal diameter (d) to the outer diameter (D) of the ON fibres (g = d/D).

Immuno-cytochemistry and Confocal Microscopy

Fixed ON embedded in Tissue Tack was frozen, sliced longitudinally (10 µm) (Leica CM3050S, Germany) and permeabilized (0.1% Triton X-100 in PBS) for 6 h (21°C) followed by blocking for 2 h with 10% goat serum [GS in PBS containing 5% bovine serum albumin (BSA) and 0.1% Triton X-100]. For KV1.1/1.2 double-staining, the primary anti-KV1.2 antibody (mouse monoclonal; NeuroMab, USA) was applied at 1∶500 dilution for 24 h (4°C) in 2% GS, 5% BSA, 0.1% Triton X-100 in PBS. After rinsing in PBS (3×20 min), sections were incubated overnight (4°C) with goat anti-mouse Alexa-568 fluor-labelled secondary antibody (Invitrogen, 1∶500) followed by washes (3×20 min) and 12 h exposure to anti-KV1.1 (rabbit polyclonal; Alomone Lab., Jerusalem). After 3 rinses, sections were incubated for 12 h in goat anti-rabbit-Alexa-488 flour labelled secondary antibodies (Invitrogen, 1∶1500), washed extensively, mounted and covered with Vectashield (Vector Labs, UK) for microscopic analysis. Specificities of the immuno-staining procedures were verified in negative controls, with omission of the primary antibodies. For NaV/KV1.2 staining, longitudinal cryosections (10 µm) of ON were placed on superfrost slides, blocked for 3 h with 10% horse serum containing 0.1% Triton X-100 (in PBS). Both polyclonal Nav and monoclonal Kv1.2 antibodies at dilutions of 1∶50 and 1∶200, respectively, were added for 24 h at room temperature, followed by 3 rinses. Subsequently, the tissue was incubated with biotinylated anti-mouse and -rabbit antibodies (Vector lab, 1∶1000) sequentially for 45 min each and developed with its corresponding streptavidin tagged flourophore (1∶1000, Alexa-488 and -568-labeled, Invitrogen) for 45 min, washed and mounted with Vectasheild for fluorescence microscopy. Field micrographs were obtained (20× objective) using a laser scanning microscope in epifluorescence mode (pinhole wide open) (AxioObserver, Carl Zeiss; Germany), while high-magnification images of JXPs were acquired in confocal mode (pinhole = 0.5AU, 40× objective) for analysis. Argon and Helium/Neon lasers provided the 488 and 568 nm lines for excitation; emitted signals were sampled in a frame mode at spatial resolution of 30 nm per pixel with 1.5 µs dwell time. The mean fluorescence intensities, fluorescent areas and co-localization of labelled KV1.1 and 1.2 α subunits were quantified with ImageJ and Zen 2008 (Carl Zeiss, Germany).

CAP Recordings from ON and Pharmacological Analysis

Mice (16–17 weeks old) were decapitated under deep anaesthesia (as above) and ON carefully transected in proximity to the sphenoid canal. Brain with attached ON was removed and immersed for 5 min in bubbled (95% O2, 5% CO2) ice-cold solution containing (in mM): sucrose, 75; NaCl, 85; KCl, 2.5; NaH2PO4, 1.25; NaHCO3, 25; CaCl2, 0.5; MgCl2 4; glucose, 25, pH 7.3 and glued in the recording chamber attached to the stage of an upright Olympus BX51WI microscope with the ON facing upward. The sample was perfused continuously throughout the experiment with bubbled (95% O2, 5% CO2) artificial cerebrospinal fluid (aCSF) containing (in mM): NaCl, 125; KCl, 3; NaH2PO4, 1.25; NaHCO3, 25; CaCl2, 2; MgCl2, 2; glucose, 25; pH 7.3 at 33–35°C. The perinervium was carefully removed with the distal end of the ON drawn into a suction electrode for stimulation. Evoked CAP recordings were made with low-resistance glass pipettes (5–15 µm tip diameter, 0.2–1.2 MΩ) filled with aCSF, which was gently inserted into the ON at close proximity to the optical chiasm to record evoked CAPs (stim. 100 µs pulse; 1.0–1.5 mA/0.03 Hz). Efforts were made to keep relatively constant the distance between the stimulation and recording electrodes at 1.0–1.2 mm. Unlike the complex shape CAP recordings of ON (Allen et al., 2006) using a suction electrode at room temperature, under our settings the CAP with glass pipette from control mice revealed a simple waveform, attributing the differences in the shapes CAP to: (1) smaller pool of axons contributing to the CAPs recorded with glass pipette (2) shorter distance between the stimulation and recordings sites with less temporal dispersion of the action potentials from population of heterogeneous axons and (3) use of temperatures close to physiological in the present study. Analog signals were acquired in episodic mode, amplified (EPC-10 USB controlled by Patchmaster 2.20; HEKA Instruments) and filtered at 10 kHz before storage for off-line analysis (Clampfit 10.0; Molecular Devices, CA). For measurement of the CAP refractory period, paired stimuli of sub-maximal intensity (1/2 max amplitude) were applied at various inter-pulse intervals, and the peak amplitude ratio of the second vs. the first (A2/A1) response was plotted as a function of the inter-stimulus intervals. Peptide blockers were aliquoted in recording solution, stored at −20°C and added to the perfusion medium before use. Dendrotoxin K (DTXK) was purified in-house; tityustoxin-Kα (TsTX-Kα) was obtained from Peptide International (Kentucky, USA). Tetraethylammonium chloride (TEA) and 4-AP were purchased from Sigma (Wicklow, Ireland) and Lancaster Synthesis (Lancaster, UK), respectively.

Heterologous Expression and Characterization of Concatenated KV1 Channels

KV1.1 or 1.2 αsubunit genes were concatenated and expressed as homo-tetramers KV(1.1)4 or KV(1.2)4 and hetero-tetramers [KV(1.1)2–(1.2)2, KV1.1-1.2-1.1-1.1]; the tandem linking of the genes used an inter-subunit linker [25] derived from the untranslated regions (UTR) of the Xenopus β-globin gene (GenBank® accession number J00978). The cDNAs were amplified using KVX sequence-specific primers, as described [26]. Correct positioning of the genes in all of the pIRES2-EGFP plasmid constructs was confirmed by restriction analysis and DNA sequencing. Constructs were expressed in HEK293 cells (American Type Cell Culture, VA, USA) and surface biotinylation was performed as reported [27]. Western blotting with mouse mAb for KV1.1 or 1.2 was followed by their visualization with a goat anti-mouse secondary antibody conjugated to horseradish peroxidase. Macroscopic currents were measured from these cells by whole-cell voltage clamp recordings (EPC10, HEKA Elektronik, Germany). Patch pipettes (in-bath resistance1.5–3.0 MΩ) were filled with an internal solution (in mM): 95 KF, 20 KCl, 1 CaCl2, 1 MgCl2, 11 EGTA, 10 HEPES, 2 Na2ATP (pH 7.2 with KOH). External medium contained (in mM): 135 NaCl, 5 KCl, 2 CaCl2, 2 MgCl2 and 5 HEPES (pH 7.4 with NaOH). The liquid junction potential was corrected and series resistance compensated (70–80%). Conductance-voltage relationships were taken from the averages of the steady-state currents (100 ms before the termination of 300 ms pulse stimuli) activated with voltages of −80 to +20 mV with 5 mV increments. The activation rates were assessed through fitting the rising phase of KV1 currents with a single exponential function. Data were analysed by Pulsefit (HEKA Electronik, Germany) and fitted/plotted using Igor Pro 6 (WaveMetrics, USA). The IC50 values for inhibitors were obtained using automated whole-cell voltage clamp system (QPatch 16, Sophion Bioscience, Ballerup, Denmark), as previously described [26], with Qplate pin-wholes having resistances 2–3 MΩ. Giga-seals were formed upon execution of a combined suction/voltage protocol; gradually increasing suction leads to the whole cell configuration. Blockers were applied, via a four-way pipetting robot, through integrated glass-coated microfluidic flow channels. Data analysis was performed using an integrated database (Oracle) within QPatch software (Sophion Bioscience, Ballerup, Denmark). Peptide toxins were diluted from frozen aqueous stocks into external recording solution containing 0.01% (w/v) BSA and their inhibitory effects determined by the Hill equation fit to 7 concentrations.

Statistical Analysis

All the data are presented as means ± S.E.M. U-Mann-Whitney, non-paired and paired Student's t-test was applied for comparison, with P<0.05 considered statistically significant.

Results

Widespread Demyelination in Axon-rich Tracts of CNS Induced by Cuprizone

CNS demyelination was established in mice fed with cuprizone for 8 weeks. The animals did not show overt signs of ataxia, seizures, anorexia or other distress except that weight loss occurred during the first 2–3 weeks. Although this was followed by a gradual gain in weight by the end point, the treated mice remained underweight compared to controls (∼10%, n = 20, p<0.05). Analysis of brain sections stained for myelin with CV or LFB revealed its depletion especially notable in white matter-rich structures such as corpus callosum, internal capsule, stripes of the caudate nucleus and cerebellar peduncle (Fig. 1A, B). As evident from the histogram of myelin density in corpus callosum, a broader range of signals of higher intensity prevailed (36.7±0.37, ROI = 171) in controls compared to the values pulled from samples of cuprizone-treated mice that yielded more uniform signal densities of lower intensities (17.9±0.22, ROI = 146) (p<0.001; Fig. 1C). Cross-correlation analysis of relative myelin densities in callosal and hippocampal CA3 regions also unveiled prominent myelin loss in the hippocampus (Fig. 1D). Likewise, myelin loss was prominent in the cerebellar region of experimental group, with its substantial depletion in the paranuclear region of deep cerebellar nuclei and peduncular structures (Fig. 1A, right hand panels and E). These histochemical findings were corroborated by quantisation of myelin content of the brain tissue, which showed its significantly lower levels in total brain and forebrain of cuprizone-treated mice (56.2±7.4% and 71.3±8.7% of control, p<0.05; n = 3 in each group; not shown).

Figure 1. Cuprizone administration to mice induces widespread demyelination in several brain structures and reduces the myelin content.

Figure 1

(A–B) Representative light micrographs of sagittal sections of brain from control and cuprizone-treated mice, respectively, stained for myelin with CV and LFB dyes. (A) Myelin is visualised in samples from the control mice, as light brown by CV and dense blue for LFB, in corpus callosum (CC), the stripes in the corpus striatum of the caudate putamen (CPu), internal capsule (IC) and the central nuclei of the cerebellar medulla (CN). (B) Extensive demyelination was observed in the above regions of treated mice. (C) Plot of the density distribution of myelin stained with LFB of defined colossal ROIs. A narrow and leftward-shift in the histogram of the density of myelin in cuprizone-treated samples reflects callosal demyelination (n = 6 in each group). (D) Correlation analysis of the density of LFB-stained myelin of random ROIs from callosal and hippocampal CA3 areas. Note the higher level of callosal myelin in controls (R2 = 0.21) compared to CA3 area, with its stronger decline in experimental samples (R2 = 0.54). (E) Summary histogram of the mean myelin density in CC and CP regions (>100 ROIs, from each group) with both areas revealing significant loss of myelin in mice that had received cuprizone. * p<0.05.

Altered Compactness of Myelin and Axonal Geometry in ON of Cuprizone-treated Mice

Structural changes in ON axons from mice that received cuprizone relative to the controls were analyzed at light and electron microscopic levels. Figure 2A depicts low power micrographs of the toluidine blue stained cross-sections of ON. Axonal counts were comparable in two groups over the equivalent areas (15814±658 vs. 14069±955 over 50 µm2, p = 0.18). An absence of visible myelin breakdown and spheroid blebs accords with the lack of axonal degeneration in this model. Yet, individual axons of treated mice appeared less annular (Fig. 2A), with an overall reduced number of large calibre fibres (Fig. 2C, lower inset). Increased peri-axonal space with segregation of axons into irregular bundles along with occasionally visible reactive macrophage-like elements was also characteristic of the experimental samples (Fig. 2A). At the ultra-structural level, loosely myelinated axons with fewer lamellae were regularly encountered in the cuprizone-treated samples whereas the controls were typically enclosed in a compact and periodic sheath of myelin (Fig. 2B). Quantitative analysis of the axonal geometry and comparison with controls confirmed a notably lower fraction of large calibre axons (D = 0.474±0.02 µm vs. D = 0.437±0.01 µm; p<0.001) with an overall reduced axon cross-sectional area (Fig. 2C, upper inset). Estimates of the relationship between myelin thickness and axon diameter (Fig. 2D) unveiled a stronger correlation of these two parameters in ON from mice that were fed with cuprizone (R2 = 0.31 vs. R2 = 0.13, cuprizone-treated vs. controls), suggestive of a greater sensitivity of the myelin sheath thickness to cuprizone as compared to the axon diameter (Fig. 2D inset). Interestingly, the concurrent decrease of both parameters in axons maintains the estimated axonal ‘g’ ratio in treated samples relatively unaltered (n = 1019 vs. n = 910; control 0.845 vs. cuprizone 0.856, p = 0.17). Taken together, the evidence from light and electron microscopic data confirm substantial demyelination of the ON with changes in the morphometry of axons in the cuprizone treated mice, without any signs of their degeneration.

Figure 2. Light- and electron-microscopic analysis of ON reveals a decrease in the compactness and loss of myelin in the experimental mice.

Figure 2

(A) Low power representative photomicrographs of ON from control and cuprizone-treated mice (TLB stained). Note less annular appearance of large diameter axons with a higher degree of intrinsic parcellation of the demyelinated nerve. (B) Electron micrographs of ON axons from control and treated mice. Along with a large number of myelinated axons (normal) with compact myelin sheaths consisting of several layers, axons covered with a loose myelin envelope of only a few lamellae were regularly encountered in the treated tissue (black arrows). (C) A summary plot of the distribution cross-sectional area of axons with insets highlighting divergence of this parameter for thicker axons (lower inset) and reduced mean cross-sectional area (upper inset) of axons in treated samples. (D) Graphical illustration of the relationship between myelin sheath thickness and axon diameter with regression lines and summary histogram of myelin thickness (inset) show a significant decrease in both parameters in treated mice.

KV1 Channel Distribution and Composition are Altered in the Demyelinated ON Axons

In myelinated axons, there is a sharp segregation of voltage-dependent ion channels at the nodes of Ranvier with NaV channels clustered within the nodal gaps while KV1 channels are located in the JXPs [28]. Both nodal and JXP regions were readily identified in control ON with pan-specific NaV antibodies delineating nodes, whilst KV1.2 reactivity was most intense adjacent to the nodal gaps, decreased towards the internodes and gradually diminished to background level (Fig. 3A1). Visibly intact nodes were also detected in ON from the cuprizone-treated mice (Fig. 3A2), albeit representing only a fraction (33.3±2.2%) with the majority showing elongated KV1.2-positive JXPs (Fig. 3A2, C). In controls, double labelling with anti-KV1.1 and 1.2 specific antibodies revealed overlapping fluorescence, with both subunits flanking most of JXPs (Fig. 3B1). In contrast, the level of KV1.1 and 1.2 in the mice receiving cuprizone appeared increased (Fig. 3D, E), with KV1.1 subunit extending with greater prominence into the internodes (Fig. 3B2, D and E). These changes are readily reflected in high magnification confocal micrographs as elongation of KV1.1 and 1.2 labelled JXPs (3A2, B2, vs. 3A1, B1), in axons of cuprizone-treated mice and accord with their overall larger JXP areas (KV1.1∶2.4±0.5 µm2 vs. 8.2±1 µm2 p = 0.006; KV1.2∶3.8±0.4 vs. 8.2±1, p = 0.01) (Fig. 3D, E). Importantly, the co-localization coefficient of KV1.1/1.2 subunits within fluorescent profiles was higher in controls (KV1.1/1.2 = 0.86±0.06) compared to significantly diminished values in ON axons of cuprizone-treated mice (KV1.1/1.2 = 0.27±0.04), suggestive of a preferential increase in the expression level of KV1.1 in demyelinated axons (Fig. 3F compared to Fig. 3G). This inference is consistent with results of quantisation of relative luminescence-intensity (ELISA) and Western blot analysis which demonstrate considerable increase in the expression of KV1.1 subunits in ON of cuprizone-treated mice (Fig. S1) [29]. Finally, probing mouse ON (both Western blotting and immuno-fluorescence) failed to detect KV1.3, 1.5 and 1.6 subunits in ON axons from both controls and cuprizone-treated ONs except for a trace amount of KV1.4 (not shown).

Figure 3. Demyelination alters the distribution and composition of KV1 channels in ON.

Figure 3

Double [pan-Na (red)/KV1.2 (green)] immuno-labelling of control (A1) and experimental (A2) ON: note elongated JXPs with alterations in most of the nodal NaV channel clusters in samples from the cuprizone-treated mice. (B1–2) Double immuno-labelling of ON for KV1.1 (red) and KV1.2 (green) subunits of KV1 channels: control (B1) and experimental (B2) samples, respectively. Note the highly localized occurrence of these proteins in JXPs of controls contrasting with their diffuse location along the ON axons in demyelinated specimens. Yellow staining corresponds to JXP regions showing co-localization of these proteins. The scale bars for low and high magnifications are 6 and 2 µm, respectively. (C) Summary histogram of the intact JXP labelled with anti-KV1.2 antibody of control and experimental ON axons (n = 3 in each group). (D) A plot of the mean area of JXPs labelled for KV1.1 channels in control (2.4±0.5 µm2) compared to the increased area of fluorescence intensity of JXPs in demyelinated (8.2±1 µm2) axons. (E) The mean fluorescence area of JXPs labelled for Kv1.2 channels in control (3.8±0.4) was lower than that in the treated ON axons (8.2±1 µm2). (F) A summary histogram of KV1.1 and 1.2 co-localization in control (0.86±0.06) and demyelinated (0.27±0.04) ON demonstrating a significant (p<0.001) reduction in the degree of KV1.1/1.2 co-localization in ON axons of the experimental mice. (G) The degree of KV1.2/1.1 co-localization in ON axons of the experimental mice showed a reduction, which is still significant (P<0.05), when comparing the control (0.71±0.06) and the demyelinated ON (0.49±0.04) values. Data are taken from control and demylinated ON axons of 3 animals, in each group.

Altered Electro-responsiveness and Conductivity of ON from Cuprizone-treated Mice

CAP recordings were obtained from the proximal stump of semi-dissected ON at physiological temperature (Fig. 4A, B inset). In controls, stimulation of the distal end of the nerve evoked synchronous responses, whose amplitude could be graded by varying the stimulus strength (Fig. 4B); the threshold intensity for CAPs ranged between 0.36 and 0.44 mA (0.39±0.2; n = 6) and saturating at stimuli between 0.9 and 1.2 mA (0.96±0.4, n = 6) (Fig. 4C). Uniform conduction of ON axons in controls was evident from synchronous monophasic CAPs evoked by a single or paired pulse stimuli, with absolute refractory phases ranging between 2.0 and 2.6 ms (2.38±0.2, n = 6) (Fig. 4E). The potential reasons for discrepancies between the synchronous CAPs observed herein and those obtained using suction electrode (Allan et al., 2006) are given in MATERIALS AND METHODS. Analysis of the effects of TEA (10 mM) or 4-AP (1 mM) on sub-maximal CAPs of the intact ONs showed a significant increase in CAP amplitude by 4-AP, but not TEA after 15–20 min exposure (7.9%; n = 5; p>0.05 vs. 38.8%; n = 5; p<0.05) (Fig. 4D, F and G). Notably, neither TEA nor 4-AP affected the 50% refractory phase of CAPs (5.3±0.3 ms and 5.4±0.2 ms; p = 0.21 and p = 0.48) in controls, with only 4-AP reducing the threshold stimulus intensity (3.3±0.4; p = 0.038) for eliciting CAPs (not shown). Unlike the controls, CAPs of ON from cuprizone-treated mice revealed a distorted shape, with an early fast phase followed by a protracted late component (Fig. 4B, D and E), reflecting temporal dispersion of action potentials of axons in the demyelinated ON. Furthermore, the minimal stimulus intensity required for eliciting CAPs in the demyelinated sample was elevated (range: 0.42 and 0.62 mA, mean: 0.58±0.3; n = 5; Fig. 4C) with the absolute refractory phase prolonged (range: 2.8 and 3.6 ms; mean: 3.0±0.2, n = 5). In demyelinated nerves, blockade of K+ channels with TEA (10 mM) or 4-AP (1 mM) notably increased CAP amplitude (37.0%; n = 5; p<0.05 vs. 57.7%; n = 5; p<0.05), with the effects of the TEA also reaching statistical significance in controls (33.0%; n = 5; p<0.05) (Fig. 4D, F and G). As observed with the controls, refractory time for 50% recovery of CAPs (7.7±0.3 ms and 7.5±0.2 ms) remained unaltered under both treatments while the threshold stimulus intensity was significantly reduced (0.47±0.1 mA and 0.46±0.1 mA; TEA and 4-AP, respectively; n = 5 in each group; p<0.05).

Figure 4. Demyelination disrupts the conductivity of ON axons which can be partially restored by 4-AP.

Figure 4

(A, B) A low magnification micrograph (4×) demonstrating the semi-dissected ON (ventral view) with stimulation (suction, Suc. pipette) and recording (Rec.) electrodes. Graded synchronous CAPs recorded from control animals contrasting with bi-component CAPs derived from experimental ON activated from elevated stimuli thresholds (C). Insert illustrates the experimental set-up for CAPs recordings. Rec. - recording electrode; Suc. - suction pipette used for stimulation. ON – optic nerve, OX – optic xiasm. (B) Typical CAPs evoked in control ON by paired-pulse stimulation (PPS). Note the second CAP from the refractory phase following the first CAP. The evoked CAPs recorded from cuprizone-treated (demyelinated) ON axons showed lower amplitudes and protracted late components compared to the untreated (myelinated) ON axons. (C) Stimulus-response relation of CAPs in controls and experimental ON, showing lower activation threshold and higher amplitudes of evoked CAPs in demyelianted ON. (D) Representative recordings of CAPs from ON of control and cuprizone fed mice before (1) in the presence of TEA (2, upper row) or 4-AP (lower row) and (1+2) superimposed traces. (F, G) Summary of the effects of TEA (15–20 min application) on the CAPs in control and cuprizone-treated ONs (n = 5 in each group) (E) The summary histogram of CAP amplitudes scored before and after application of 1 mM 4-AP. Note the significant enhancement of the CAP amplitudes in demyelinated ON caused by 4- AP (P<0.05, n = 5 in each group).

Differential Contribution of KV1.1 and KV1.2 to CAP in Demyelinated ON

Despite the presence of KV1.1 and 1.2 subunits in normal and demyelinated ON as demonstrated above, their relative contribution to tuning the electrogenic properties of axons therein remained elusive. Exposure of control ON to the potent blockers of KV1.1 and 1.2 subunits, DTXK (100 nM) or TsTX-Kα (100 nM), respectively, caused no alterations in the characteristics of CAPs (Fig. 5A1, B1), with both amplitude and activation threshold remaining relatively unaltered (amplitude increase: 15±7.2%, n = 5; 10.3±5.8%, p>0.05; n = 6, respectively) (Fig. 5A2, B2). At the specified concentrations, DTXK is known to block completely KV1.1-containing channels (IC50 of 2.5 nM) [30], [31] while TsTX-Kα abolishes K+ currents mediated by KV1.2 channels (IC50 of 0.55 nM) [32]. Because of the strong presence of both subunits in mouse ON JXPs (Fig. 3A1, B1), the ineffectiveness of such toxin blockers in intact axons is likely to be due to poor accessibility of the K+ channels. In stark contrast, in demyelinated nerves, the same concentrations of DTXK and TsTX-Kα caused significant augmentation of the CAP amplitude (74.3±5.4%, n = 5; 32.2±4.2%, n = 5; respectively, p<0.05) with the late asynchronous component being particularly enhanced (Fig. 5A and B). Concurrently, both current thresholds (72.5% decrease with DTXK; 22.8% decrease with TsTX-Kα; P<0.05) and 50% refractory time were notably reduced, albeit the latter reached statistical significance only in DTXK treated samples (61.3±7.1%, n = 5 vs. 13.2±3.1%, n = 6; p = 0.01 and p>0.05, respectively). The quantitatively different effects of these blockers was unexpected given that the presence of a single toxin-sensitive subunit renders hetero-tetrameric channels susceptible to toxins [33], and suggests that enhanced K+ conductance in demyelinated axons could be mediated largely, but not exclusively, through KV1.1 homo-tetrameric channels.

Figure 5. A more promenant contribution of KV1.1 than 1.2 subunits of Kv channels in regulating the excitability and conductivity of demyelinated ON.

Figure 5

(A1, B1) Representative CAP recordings demonstrating the effects of DTXK and TsTX-Kα respectively, before (1) and 40 min after presentation of the toxins to the control and experimental ONs (2). (A2, B2) Time course of the effects of DTXK and TsTX-Kα, respectively, on evoked CAPs (sub-maximal) of control (filled circle; n = 5; n = 6) and experimental (open circle; n = 5; n = 5), respectively. Black arrows indicate the start of the application of toxins. Note a slight increase in the CAPs by these toxin blockers in controls (A1, B1, filled circle) compared to much stronger enhancement of CAPs in demyelinated ON by TsTX-Kα (B1 and B2) and especially DTXK (A1 and A2).

KV1.1 Subunits Lower the Activation Threshold and Speed-up Activation Kinetics of KV1 Channels Recombinantly Expressed in Mammalian Cells

To examine how demyelination-associated enrichment of KV1 channels with KV1.1 subunit could affect their functional properties, biophysical profiles of the currents mediated by concatenated homo-KV(1.1)4 or KV(1.2)4 and hetero-tetramers (KV1.1-1.2-1.1-1.1, KV1.1-1.1-1.2-1.2) were analysed. Expression of these tetramers in mammalian HEK293 cells was confirmed by surface biotinylation of the intact cells and Western blotting with anti-KV1.1 or 1.2 specific antibodies. This revealed a single band of the expected size (Mr ∼250 kD) for channels expressed on the plasmalemma (Fig. 6A), and their functionality was demonstrated by whole cell recordings. Each mediated voltage-activated non-inactivating K+ currents, which were consistently larger in cells expressing KV1.2 homo-tetramers or those containing this subunit together with KV1.1 (Fig. 6 D1-F1). Most importantly, KV1.1 homo-tetrameric channels activated at less depolarized thresholds than the currents resulting from the others (Fig. 5 D2-F2).This feature is reflected clearly in conductance-voltage (gK-V) plot of the K+ currents, with KV(1.1)4 activating from significantly more hyperpolarized potentials (close to -60 mV) compared to the KV1.1-1.2-1.1-1.1, KV1.1-1.1-1.2-1.2 and KV(1.2)4 channels (Fig. 6 D2-F2, Table 1). In all cells, the gK-V relationships of the K+ currents were fitted well with a Boltzmann function with half-maximal values of activation (V1/2) for KV(1.1)4 being most negative followed by intermediate potentials for the currents mediated by KV1.1-1.2-1.1-1.1 or KV1.1-1.1-1.2-1.2, and the most depolarised values observed with KV(1.2)4 channels (Table 1). Interestingly, significant differences were also observed between activation rates of these currents at near-threshold potentials, with KV(1.1)4 channel displaying a faster activation rate than the others (Fig. 6 B and C, D inset; Table 1).

Figure 6. Functional characterization of recombinant KV1.1 homo-tetramers reveals distinctive biophysical profiles from those of KV1.1/1.2 heteromers.

Figure 6

(A) Western blots of surface expressed concatenated KV1 channels in[HEK293 cells. Lanes: 1, non-transfected cells show no immuno-reactivity for KV1.1 (or KV1.2, not shown); 2, KV(1.1)4 and 3, KV1.1-1.1-1.2-1.1 detected with anti-KV1.1 IgG giving a band size of ∼250 kD; 4 and 6, KV(1.2)4 homo-tetramer was non-reactive with anti-KV1.1 IgG (4) but gave a distinct band when probed with KV1.2 IgG (6). Protein markers are indicated in lanes 5 and 7. (B, D1–F1) Representative recordings of macroscopic currents (300 ms pulse) from HEK293 cells transfected with the individual recombinant channels. (B, C) Activation rate of the voltage-dependent K+ currents mediated by KV(1.1)4 (left) and KV(1.2)4 (middle) channels (within the range of 10–30% of max. current) at 5 mV from indicated voltages (below) with super-imposed (right) representative traces from. A notable difference between the rates of activation of KV(1.1)4 and KV(1.2)4 is revealed by fitting the data with a single exponential (see C). (D2–F2) Conductance-voltage relations of macroscopic currents measured, based on the K+ current of the last 100 ms for each channel. Conductance at various command potentials were normalised and fitted with a single Boltzmann function. The difference in conductance values of KV(1.1)4 and KV(1.2)4 channel were statistically significant from −55 mV (P<0.05, Mann-Whitney U-test, see Table 1 for summary of the biophysical data).

Table 1. V½ for activation and onset rate of currents mediated by the different recombinant channels expressed in HEK293 cells.

Parameters KV(1.1)4 KV1.1-1.2-1.1-1.1 KV1.1-1.2-1.1-1.1 KV(1.1)4
V1/2 (mV) −35±1(6) **−20±1(10) #**−17±1(9) **−7±1(8)
tau1/2 (ms) 13±2(6) *18±1(8) **24±1(8) **29±2(8)

Results are represented as means ±S.E.M. (n-values);

*

(p<0.05) and ** (p<0.005) numbers are significant compared to those from KV(1.1)4, (Mann Whitney U-test);

#

data are taken from Al-Sabi et al., (2010).

KV1.1- and KV1.2-containing Channels can be Distinguished by Selective Blockers

HEK293 cells expressing channels composed of homomeric KV(1.1)4, (1.2)4 or heteromeric combinations of both subunits [KV1.1-1.2-1.1-1.1 and [KV(1.1)2-KV(1.2)2] were used to mimic those possibly present in demyelinated ON axons. DTXK potently and selectively inhibited only the KV1.1 homo-tetrameric channels, with sub-nanomolar IC50 (Table 2); introduction of a single KV1.2 subunit into the tetramer (KV1.1-1.2-1.1-1.1) lowered its susceptibility to blockade by DTXK. Having two copies of KV1.2 and KV1.1 subunits in the concatamer (KV1.1-1.1-1.2-1.2), resulted in an even lower sensitivity to DTXK (IC50>100 nM). On the other hand, KV(1.2)4 channel was blocked by TsTX-Kα but apparently insensitive to DTXK (Table 2). The K+ current elicited by a heteromeric channel with equal numbers of KV1.1 and 1.2 subunits proved ∼6 -fold less sensitive to TsTX-Kα than KV(1.2)4. Furthermore, TsTX-Kα failed to block KV1 channels containing 3 or 4 copies of KV1.1 subunits. Collectively, these results showed that DTXK and TsTX-Kα are potent inhibitors of K+ currents mediated by KV1 channels that contain at least three copies of KV1.1 or two copies of 1.2 subunits, respectively.

Table 2. Differential inhibition of concatenated KV1 channels expressed in HEK293 cells by DTXK and TsTX-Kα.

IC50 (nM) DTXK TsTX-Kα
KV(1.1)4 0.27±0.07 (5) >100 (3)#
KV1.1-1.2-1.1-1.1 *4±0.1 (4) >100 (3)
KV1.1-1.2-1.2-1.2 >100 (4) 15±2 (4)#
KV(1.2)4 >100 (3) 2.6±0.2 (3)#

Results are represented as means ±S.E.M.; n-values are in brackets;

*

(p<0.05) numbers are significant compared to KV(1.1)4 (t-test),

#

Data were taken from Al-Sabi et al., (2010).

Discussion

The pervasive correlation between inflammatory optic neuropathies and symptoms of clinical MS, manifested by disruptions of visual functions, renders the ON an attractive experimental model. Being an anatomical extension of the forebrain [34], ON share key features of central myelinated tracts under healthy and disease conditions. Herein, a substantial demyelination with reduction of the myelin compactness and shrinkage of thick axons were demonstrated in ON from cuprizone-fed mice. Although the majority of nodes enriched with Na+ channels remained relatively intact, most of the JXPs became elongated due to spread and ectopic appearance of K+ channels composed of KV1.1 and 1.2 subunits in the inter-nodes, albeit with a disproportionate increase in the level of KV1.1. This inquisitive observation accords with the functional data from CAP recordings which highlighted better restoration of ON conductivity with DTXK-(KV1.1-selective) compared to TsTX-Kα (KV1.2-selective). Assessment of the K+ current mediated by recombinant (KV1.1)4 homo-tetrameric channels in HEK293 cells revealed a lower activation threshold and faster kinetics than those recorded for (KV1.2)4 homo-tetramers or KV1.2 subunit-containing hetero-tetramers. Thus, along with the demonstration of myelin loss and a decrease in the axon diameter, our data also provide important insights into demyelination-related changes in the molecular composition of KV1 channels in central axons, which could be of potential relevance to MS and other disease associated with the loss of myelin.

ON Demyelination in Cuprizone-treated Mice: Relevance to MS

Models of virally- or chemically-induced (including by cuprizone) demyelination and experimental autoimmune-allergic encephalomyelitis have been widely used for studying de- and re-myelination processes in the CNS [35], [36]. High reproducibility with scattered lesions in the white matter, accompanied by edema and astrogliosis caused by cuprizone closely mimic changes occurring in the CNS during MS [37], [38]. Although some brain regions seem to be more sensitive to cuprizone than others, the widespread CNS demyelination involving corpus callosum, hippocampus, cerebellum, basal ganglia and other white matter rich brain structures have been documented [38], [39], [40]. In addition to reduced myelin content of the forebrain and cerebellum, we demonstrate for the first time pronounced myelin depletion of the ON in mice fed cuprizone. Indeed, electron microscopic analysis highlights reduction in the myelin thickness and compactness, along with shrinkage of the large diameter axons associated with the emergence of loose myelin stacks and sub-axolemmal vacuolar elements. A complete lack of myelin breakdown or axonal spheroid blebs in our experimental samples accord with an absence of degeneration of axons and neurons reported for this model [40]. Similar signs of axonopathy with reduction in the axonal caliber followed by degeneration at the later stages have been reported for transgenic mice lacking myelin proteins such as 2′,3′cyclic nucleotide 3′-phosphodiesterase, proteolipid protein and myelin-associated glycoprotein [41], [42] as well as in autopsies from MS brain [37]. These changes in axonal ultra-structure have been attributed to the fact that oligodendrocytes and myelin integrity, in addition to providing insulation, supply trophic support to axons which is essential for stability and normal functionality [43], [44]. Interestingly, the decrease in the myelin thickness of axons in our model was associated with moderate reduction of their diameter, perhaps a compensatory process, which retained the ‘g-ratio’ fairly normal. In fact, smaller axon diameter would reduce the capacitative load, favouring more effective propagation of action potentials through demyelinated segments; also, it would assist in maintaining ion homeostasis, delaying the onset of irreversible degeneration and neurological decline [45], [46]. It should be emphasized that even though the extent to which cuprizone demyelination reflects MS pathology in humans remains disputable [38], [39], extensive breakdown of myelin with its depletion in ON documented herein suggest this model as being useful and appropriate for exploring certain aspects of MS patho-biology.

Functional Impact of Aberrant KV1 Channels in Demyelinated Axons

Even though clustering of Na+ channels in axons does not require the myelination process and developmentally precedes it, their lateral diffusion during demyelination suggests a stabilizing influence of axo-glial signalling on nodal Na+ channel clusters [47], [48]. In contrast, the myelin integrity appears to be mandatory for targeting K+ channels to JXPs [28], [49]. Accordingly, although antibodies to KV1.1 and 1.2 subunit labelled numerous JXPs in cuprizone-treated mice, many of these specializations were greatly elongated with KV1 proteins present in internodes, consistent with earlier documented dislocation of axonal K+ channels from their canonical sites in demyelination animal models and MS brain [49], [50]. Curiously, these changes in the distribution of KV1 channels appear to be associated with alterations of their molecular constituents, with co-localization analysis indicating disproportionate gain in KV1.1 immuno-reactivity with a notable advancement into the internodes of the demyelinated axons. In light of the established co-assembly of KV1.1 and 1.2 at JXPs throughout the brain [31], [49], preferential increase in the content of KV1.1 expression in the experimental mice suggests de-novo synthesis and post-translational enrichment of KV1 channels with this protein and, perhaps, expression of KV1.1 homo-tetramers. Notably, an asymmetric gain in the level of KV1.1 under demyelination has been demonstrated indirectly by in situ hybridization studies on shiverer mice. Affected by deletion of the 5′ exons of a gene encoding myelin basic protein, this model revealed much greater elevation in the level of KV1.1 transcripts (compared with KV1.2) [51]. Thus, along with stabilizing KV1 channels at JXPs, our data implicate an important role of axo-glial interactions in regulating their subunit composition. It is worth stressing that the occurrence of KV1.1 in the absence of other members of KV1 family has also been revealed in a minority of healthy peripheral axons but yet of unknown functionality [52].

Concurrently, electrophysiological data demonstrate partial restoration of CAPs and shortening of the refractive phase in demyelinated ON by KV1 channel blockers. Unlike CAPs in controls that are sensitive to 4-AP, in ON from mice treated with cuprizone, both TEA and 4-AP enhanced the population response. Nodal location of channels sensitive to 4-AP but not TEA may explain the discrepancy between the effects of these blockers. Such an interpretation is consistent with earlier studies, which demonstrated two pharmacologically-distinct K+ channel types, TEA and 4-AP-sensitive, in adult ON [53]. Because 4-AP (but not TEA) is able to diffuse through biological membranes [54], it could also act as an internal blocker of channels located in paranodal and internodal segments of healthy axons, another possible explanation of the differences between their effects. Interestingly, our data contrast with those from sciatic nerve where CAPs are insensitive to these blockers prior to and after their demyelination (Bostock et al., 1981). While improved conductivity of ON by 4-AP accords with its beneficial effects documented in MS clinical trials [12], [55], the broad spectrum of actions including pro-convulsive effects hinder its widespread use for MS therapy. Similar electrophysiological experiments with DTXK and TsTX-Kα as KV1 channel blockers revealed the former be more effective in restoring CAPs in demyeliated axoms. It is worth stressing that in demyelinated samples these toxin blockers enhanced primarily the asynchronous late phase of CAPs, an effect attributable to their preferential action on slow conducting with compromised axon myelin sheath and enriched with ectopic KV1 channels accessible to these peptides. Because the relative strengths of K+ and Na+ currents in axons is a primary determinant of successful propagation of action potentials [9], the greater rescue of ON functions by DTXK accords with enrichment of demyelinated axons with KV1.1-containing heteromers or homo-tetrameric KV1.1 channels.

Implications for MS and other Demyelinating Disorders of the Central Nervous System

A well-established molecular mechanism for stabilizing the membrane potential of demyelinated axons is provided by Na+/K+ ATPase which, due to its electrogenic nature, provides a persistent hyperpolarizing drive during sustained activity, moving the axonal membrane potential away from the firing threshold [56]. An over-expression of K+ channels enriched with KV1.1 subunits in the ON axons from cuprizone-fed mice provides another, perhaps, equally powerful means for stabilizing the membrane potential at sub-threshold voltages. Unlike genetic knock-down of KV1.2 subunit (the main partner of KV1.1) associated with reduced excitability of central neurons [57], KV1.1 null mutants exhibit hyper-excitability and augmented axonal conductivity [6], [58], suggesting a powerful dampening influence of KV1.1-chonating channels on neuronal responsiveness. Indeed, the faster activation from more negative potentials of the K+ current mediated by Kv1.1 subunit-dominated channels in HEK 293 cells could restrain and stabilize the axonal membrane at sub-threshold potentials. Considering the selective increase and ectopic expression of KV1.1 subunit in axons of demyelinated ON in relation to restoration of conductivity by DTXK point to this being a potential target for ameliorative interventions. The sparse information available on specific molecular alterations responsible for impaired conductivity of demyelinated axons along with the poor selectivity of small KV channel blockers with their considerable adverse effects have greatly hampered the development of effective restorative means. Interference of 4-AP, one of the most promising candidates, with remyelination and regeneration of impaired oligodendrocytes [59] renders its clinical use for rescuing axonal conductivity problematic; this stresses the urgent need for identification and evaluation of novel drug candidates. Hence, the recognition herein of novel KV1 channels enriched with KV1.1 subunit represent a significant step forward towards the development of a specific extra-cellular blocker of such channels with potential for recovering the conductivity of demyelinated axons. Nevertheless, research on human specimens is warranted to ascertain if the demyelination-associated changes in the composition of KV1 channels described herein is applies to central axons affected by MS.

Supporting Information

Figure S1

(A, B) Quantification of the KV1.1 and KV1.2 α subunits in detergent-solubilized extracts of optic nerve, using Western blot (WB) analysis (A) and chemiluminisence ELISA (B). (A) Representative blots of KV1.1 and KV1.2 subunits of KV1 channel from mouse optic nerve. Mouse monoclonal IgGs for KV1.1 and 1.2 were used for detecting the protein (bands) of interest. The positions of markers shown on the left side indicate the molecular weight (kD). For Western blotting 15 µg crude membrane protein was loaded on each track of the gel. Note considerably denser KV1.1 band for material from cuprizone-treated mice. (B) ELISA based quantification of KV1.1 subunit protein shows significant increase of its level in an extract of optic nerve from cuprizone-treated mice (p<0.05; paired Student’s t-test). The signals were quantified as relative luminescence intensity; the relative values for untreated control and cuprizone-treated sample derived from the known standards are presented (for further details, Bagchi, 2013).

(DOC)

Funding Statement

This research was supported by a PI grant (to J.O.D.) from Science Foundation Ireland, and the Neuroscience section of the Programme for Research in Third Level Institutions (PRTLI) Cycle 4 (to S.V.O.). The PRTLI is co-funded through the European Regional Development Fund (ERDF), part of the European Union Structural Funds Programme 2007–2013. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1. Trapp BD, Nave KA (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31: 247–269. [DOI] [PubMed] [Google Scholar]
  • 2. Weinstock-Guttman B, Ramanathan M (2012) Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS. Nat Rev Neurol 8: 66–68. [DOI] [PubMed] [Google Scholar]
  • 3. Salzer JL (2003) Polarized domains of myelinated axons. Neuron 40: 297–318. [DOI] [PubMed] [Google Scholar]
  • 4. Rasband MN (2011) Composition, assembly, and maintenance of excitable membrane domains in myelinated axons. Semin Cell Dev Biol 22: 178–184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Rhodes KJ, Monaghan MM, Barrezueta NX, Nawoschik S, Bekele-Arcuri Z, et al. (1996) Voltage-gated K+ channel beta subunits: expression and distribution of Kv beta 1 and Kv beta 2 in adult rat brain. J Neurosci 16: 4846–4860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Smart SL, Lopantsev V, Zhang CL, Robbins CA, Wang H, et al. (1998) Deletion of the K(V)1.1 potassium channel causes epilepsy in mice. Neuron 20: 809–819. [DOI] [PubMed] [Google Scholar]
  • 7. Chiu SY, Zhou L, Zhang CL, Messing A (1999) Analysis of potassium channel functions in mammalian axons by gene knockouts. J Neurocytol 28: 349–364. [DOI] [PubMed] [Google Scholar]
  • 8. McDonald WI, Sears TA (1969) Effect of demyelination on conduction in the central nervous system. Nature 221: 182–183. [DOI] [PubMed] [Google Scholar]
  • 9. Bostock H, Sears TA, Sherratt RM (1981) The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol 313: 301–315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Sherratt RM, Bostock H, Sears TA (1980) Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 283: 570–572. [DOI] [PubMed] [Google Scholar]
  • 11. Goodman AD, Hyland M (2010) Dalfampridine in multiple sclerosis. Drugs Today (Barc) 46: 635–639. [DOI] [PubMed] [Google Scholar]
  • 12. Judge SI, Bever CT Jr (2006) Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 111: 224–259. [DOI] [PubMed] [Google Scholar]
  • 13. Smith KJ, Felts PA, John GR (2000) Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 123 (Pt 1): 171–184. [DOI] [PubMed] [Google Scholar]
  • 14. Molgo J, Lundh H, Thesleff S (1980) Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol 61: 25–34. [DOI] [PubMed] [Google Scholar]
  • 15. Perreault P, Avoli M (1991) Physiology and pharmacology of epileptiform activity induced by 4-aminopyridine in rat hippocampal slices. J Neurophysiol 65: 771–785. [DOI] [PubMed] [Google Scholar]
  • 16.Perry VH, Phill D (2005) Inflamation and axon degeneration.; Waxman SG, editor. Amsterdam: Elsevier Academic Press. 241–253 p. [Google Scholar]
  • 17. Arnold DL (2005) Changes observed in multiple sclerosis using magnetic resonance imaging reflect a focal pathology distributed along axonal pathways. J Neurol 252 Suppl 5v25–29. [DOI] [PubMed] [Google Scholar]
  • 18. Soderstrom M (2001) Optic neuritis and multiple sclerosis. Acta Ophthalmol Scand 79: 223–227. [DOI] [PubMed] [Google Scholar]
  • 19. Matsushima GK, Morell P (2001) The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11: 107–116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Norton WT, Poduslo SE (1973) Myelination in rat brain: method of myelin isolation. J Neurochem 21: 749–757. [DOI] [PubMed] [Google Scholar]
  • 21. Ovsepian SV, Steuber V, Le Berre M, O’Hara L, O’Leary VB, et al. (2013) A defined heteromeric KV1 channel stabilizes the intrinsic pacemaking and regulates the output of deep cerebellar nuclear neurons to thalamic targets. J Physiol 591: 1771–1791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Kamencic H, Griebel RW, Lyon AW, Paterson PG, Juurlink BH (2001) Promoting glutathione synthesis after spinal cord trauma decreases secondary damage and promotes retention of function. Faseb J 15: 243–250. [DOI] [PubMed] [Google Scholar]
  • 23. Pilati N, Barker M, Panteleimonitis S, Donga R, Hamann M (2008) A rapid method combining Golgi and Nissl staining to study neuronal morphology and cytoarchitecture. J Histochem Cytochem 56: 539–550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Ovsepian SV, Dolly JO, Zaborszky L (2012) Intrinsic voltage dynamics govern the diversity of spontaneous firing profiles in basal forebrain noncholinergic neurons. J Neurophysiol 108: 406–418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Sokolov MV, Shamotienko O, Dhochartaigh SN, Sack JT, Dolly JO (2007) Concatemers of brain Kv1 channel alpha subunits that give similar K+ currents yield pharmacologically distinguishable heteromers. Neuropharmacology 53: 272–282. [DOI] [PubMed] [Google Scholar]
  • 26. Al-Sabi A, Shamotienko O, Dhochartaigh SN, Muniyappa N, Le Berre M, et al. (2010) Arrangement of Kv1 alpha subunits dictates sensitivity to tetraethylammonium. J Gen Physiol 136: 273–282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Al-Sabi A, Kaza S, Le Berre M, O’Hara L, Bodeker M, et al. (2011) Position-dependent attenuation by Kv1.6 of N-type inactivation of Kv1.4-containing channels. Biochem J 438: 389–396. [DOI] [PubMed] [Google Scholar]
  • 28. Rasband MN, Shrager P (2000) Ion channel sequestration in central nervous system axons. J Physiol 525 Pt 1: 63–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bagchi B (2013) Myelin disruption and ectopic KV1 channels in mouse optic nerve axons of cuprizone-induced model of demyelination contributes to aberrant conduction [Ph.D. ]. Dublin: Dublin City University. 222 p. [Google Scholar]
  • 30. Robertson B, Owen D, Stow J, Butler C, Newland C (1996) Novel effects of dendrotoxin homologues on subtypes of mammalian Kv1 potassium channels expressed in Xenopus oocytes. FEBS Lett 383: 26–30. [DOI] [PubMed] [Google Scholar]
  • 31. Wang FC, Parcej DN, Dolly JO (1999) alpha subunit compositions of Kv1.1-containing K+ channel subtypes fractionated from rat brain using dendrotoxins. Eur J Biochem 263: 230–237. [DOI] [PubMed] [Google Scholar]
  • 32. Hopkins WF (1998) Toxin and subunit specificity of blocking affinity of three peptide toxins for heteromultimeric, voltage-gated potassium channels expressed in Xenopus oocytes. J Pharmacol Exp Ther 285: 1051–1060. [PubMed] [Google Scholar]
  • 33. Akhtar S, Shamotienko O, Papakosta M, Ali F, Dolly JO (2002) Characteristics of brain Kv1 channels tailored to mimic native counterparts by tandem linkage of alpha subunits: implications for K+ channelopathies. J Biol Chem 277: 16376–16382. [DOI] [PubMed] [Google Scholar]
  • 34.Brodal P (2004) The central nervous system: structure and function. Oxford: Oxford University Press.
  • 35. Steelman AJ, Thompson JP, Li J (2012) Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication. Neurosci Res 72: 32–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Stidworthy MF, Genoud S, Suter U, Mantei N, Franklin RJ (2003) Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol 13: 329–339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Dutta R, Chang A, Doud MK, Kidd GJ, Ribaudo MV, et al. (2011) Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol 69: 445–454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Kipp M, Clarner T, Dang J, Copray S, Beyer C (2009) The cuprizone animal model: new insights into an old story. Acta Neuropathol 118: 723–736. [DOI] [PubMed] [Google Scholar]
  • 39. Torkildsen O, Brunborg LA, Thorsen F, Mork SJ, Stangel M, et al. (2009) Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. Exp Neurol 215: 160–166. [DOI] [PubMed] [Google Scholar]
  • 40. Acs P, Komoly S (2012) Selective ultrastructural vulnerability in the cuprizone-induced experimental demyelination. Ideggyogy Sz 65: 266–270. [PubMed] [Google Scholar]
  • 41. Nave KA (2011) Myelination and the trophic support of long axons. Nat Rev Neurosci 11: 275–283. [DOI] [PubMed] [Google Scholar]
  • 42. Nave KA, Trapp BD (2008) Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 31: 535–561. [DOI] [PubMed] [Google Scholar]
  • 43. Klugmann M, Schwab MH, Puhlhofer A, Schneider A, Zimmermann F, et al. (1997) Assembly of CNS myelin in the absence of proteolipid protein. Neuron 18: 59–70. [DOI] [PubMed] [Google Scholar]
  • 44. Yin X, Crawford TO, Griffin JW, Tu P, Lee VM, et al. (1998) Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci 18: 1953–1962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Nashmi R, Fehlings MG (2001) Mechanisms of axonal dysfunction after spinal cord injury: with an emphasis on the role of voltage-gated potassium channels. Brain Res Brain Res Rev 38: 165–191. [DOI] [PubMed] [Google Scholar]
  • 46. Swadlow HA, Kocsis JD, Waxman SG (1980) Modulation of impulse conduction along the axonal tree. Annu Rev Biophys Bioeng 9: 143–179. [DOI] [PubMed] [Google Scholar]
  • 47. Coman I, Aigrot MS, Seilhean D, Reynolds R, Girault JA, et al. (2006) Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis. Brain 129: 3186–3195. [DOI] [PubMed] [Google Scholar]
  • 48. Poliak S, Gollan L, Salomon D, Berglund EO, Ohara R, et al. (2001) Localization of Caspr2 in myelinated nerves depends on axon-glia interactions and the generation of barriers along the axon. J Neurosci 21: 7568–7575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Rasband MN, Trimmer JS, Peles E, Levinson SR, Shrager P (1999) K+ channel distribution and clustering in developing and hypomyelinated axons of the optic nerve. J Neurocytol 28: 319–331. [DOI] [PubMed] [Google Scholar]
  • 50. Waxman SG (2006) Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci 7: 932–941. [DOI] [PubMed] [Google Scholar]
  • 51. Wang H, Allen ML, Grigg JJ, Noebels JL, Tempel BL (1995) Hypomyelination alters K+ channel expression in mouse mutants shiverer and Trembler. Neuron 15: 1337–1347. [DOI] [PubMed] [Google Scholar]
  • 52. Rasband MN, Trimmer JS, Schwarz TL, Levinson SR, Ellisman MH, et al. (1998) Potassium channel distribution, clustering, and function in remyelinating rat axons. J Neurosci 18: 36–47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Gordon TR, Kocsis JD, Waxman SG (1988) Evidence for the presence of two types of potassium channels in the rat optic nerve. Brain Res 447: 1–9. [DOI] [PubMed] [Google Scholar]
  • 54. Choquet D, Korn H (1992) Mechanism of 4-aminopyridine action on voltage-gated potassium channels in lymphocytes. J Gen Physiol 99: 217–240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Stefoski D, Davis FA, Faut M, Schauf CL (1987) 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 21: 71–77. [DOI] [PubMed] [Google Scholar]
  • 56. Bostock H, Grafe P (1985) Activity-dependent excitability changes in normal and demyelinated rat spinal root axons. J Physiol 365: 239–257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Brew HM, Gittelman JX, Silverstein RS, Hanks TD, Demas VP, et al. (2007) Seizures and reduced life span in mice lacking the potassium channel subunit Kv1.2, but hypoexcitability and enlarged Kv1 currents in auditory neurons. J Neurophysiol 98: 1501–1525. [DOI] [PubMed] [Google Scholar]
  • 58. Brew HM, Hallows JL, Tempel BL (2003) Hyperexcitability and reduced low threshold potassium currents in auditory neurons of mice lacking the channel subunit Kv1.1. J Physiol 548: 1–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Bacia A, Wollmann R, Soliven B (2004) K+ channel blockade impairs remyelination in the cuprizone model. Glia 48: 156–165. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Figure S1

(A, B) Quantification of the KV1.1 and KV1.2 α subunits in detergent-solubilized extracts of optic nerve, using Western blot (WB) analysis (A) and chemiluminisence ELISA (B). (A) Representative blots of KV1.1 and KV1.2 subunits of KV1 channel from mouse optic nerve. Mouse monoclonal IgGs for KV1.1 and 1.2 were used for detecting the protein (bands) of interest. The positions of markers shown on the left side indicate the molecular weight (kD). For Western blotting 15 µg crude membrane protein was loaded on each track of the gel. Note considerably denser KV1.1 band for material from cuprizone-treated mice. (B) ELISA based quantification of KV1.1 subunit protein shows significant increase of its level in an extract of optic nerve from cuprizone-treated mice (p<0.05; paired Student’s t-test). The signals were quantified as relative luminescence intensity; the relative values for untreated control and cuprizone-treated sample derived from the known standards are presented (for further details, Bagchi, 2013).

(DOC)


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES